Evidence map›Paper›PMID 25616667›Full record

ArticleBrain : a journal of neurology2015

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

An Goris, Ine Pauwels, Marte W Gustavsen, Brechtje van Son, Kelly Hilven, Steffan D Bos, Elisabeth Gulowsen Celius, Pål Berg-Hansen, Jan Aarseth, Kjell-Morten Myhr and 37 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Genetic determinants of the humoral immune response in MS.Neurology(R) neuroimmunology & neuroinflammation · 2020
    Observational
  17. Article
  18. Article
  19. G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis.Annals of clinical and translational neurology · 2018
    Article
  20. Genetics of Multiple Sclerosis: An Overview and New Directions.Cold Spring Harbor perspectives in medicine · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors at 20 institutions in 9 countries.

An Goris1 Laboratory for Neuroimmunology, Section of Experimental Neurology, Department of Neurosciences, KU Leuven - University of Leuven, Leuven, Belgium an.goris@med.kuleuven.be.
Ine Pauwels1 Laboratory for Neuroimmunology, Section of Experimental Neurology, Department of Neurosciences, KU Leuven - University of Leuven, Leuven, Belgium.
Marte W Gustavsen2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway 3 Institute of Clinical Medicine, University of Oslo, Norway.
Brechtje van Son4 Department of Neurology, University Hospitals Leuven, KU Leuven - University of Leuven, Leuven, Belgium.
Kelly Hilven1 Laboratory for Neuroimmunology, Section of Experimental Neurology, Department of Neurosciences, KU Leuven - University of Leuven, Leuven, Belgium.
Steffan D Bos2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway 3 Institute of Clinical Medicine, University of Oslo, Norway.
Elisabeth Gulowsen Celius2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway.
Pål Berg-Hansen2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway 3 Institute of Clinical Medicine, University of Oslo, Norway.
Jan Aarseth5 Norwegian MS-Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Kjell-Morten Myhr5 Norwegian MS-Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway 6 KG Jebsen Centre for MS-research, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Sandra D'Alfonso7 Department of Health Sciences, University of Eastern Piedmont, Novara, Italy 8 Interdisciplinary Research Centre of Autoimmune Diseases IRCAD, University of Eastern Piedmont, Novara, Italy.
Nadia Barizzone7 Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.
Maurizio A Leone8 Interdisciplinary Research Centre of Autoimmune Diseases IRCAD, University of Eastern Piedmont, Novara, Italy 9 Neurology Unit, Scientific Institute, Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.
Filippo Martinelli Boneschi11 Laboratory of Genetics of Neurological Complex Disorders, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy 11 Laboratory of Genetics of Neurological Complex Disorders, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Melissa Sorosina11 Laboratory of Genetics of Neurological Complex Disorders, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Giuseppe Liberatore10 Department of Neuro-rehabilitation, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy 11 Laboratory of Genetics of Neurological Complex Disorders, Institute of Experimental Neurology (INSPE), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Ingrid Kockum12 Neuroimmunology Unit, Department of Clinical Neuroscience, Centrum for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Tomas Olsson12 Neuroimmunology Unit, Department of Clinical Neuroscience, Centrum for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Jan Hillert13 Multiple Sclerosis Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lars Alfredsson14 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sahl Khalid Bedri13 Multiple Sclerosis Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Bernhard Hemmer15 Department of Neurology, Technische Universität München, Munich, Germany 16 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Dorothea Buck15 Department of Neurology, Technische Universität München, Munich, Germany.
Achim Berthele15 Department of Neurology, Technische Universität München, Munich, Germany.
Benjamin Knier15 Department of Neurology, Technische Universität München, Munich, Germany.
Viola Biberacher15 Department of Neurology, Technische Universität München, Munich, Germany.
Vincent van Pesch17 Institute of Neurosciences, Neurochemistry Unit, Université Catholique de Louvain-la-Neuve, Louvain-la-Neuve, Belgium.
Christian Sindic17 Institute of Neurosciences, Neurochemistry Unit, Université Catholique de Louvain-la-Neuve, Louvain-la-Neuve, Belgium.
Annette Bang Oturai18 Danish Multiple Sclerosis Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Helle Bach Søndergaard18 Danish Multiple Sclerosis Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Finn Sellebjerg18 Danish Multiple Sclerosis Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Poul Erik H Jensen18 Danish Multiple Sclerosis Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Manuel Comabella19 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Xavier Montalban19 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jennifer Pérez-Boza19 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sunny Malhotra19 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jeannette Lechner-Scott20 Hunter Medical Research Institute, University of Newcastle, Australia.
Simon Broadley21 School of Medicine, Gold Coast Campus, Griffith University QLD 4222, Australia.
Mark Slee1 Laboratory for Neuroimmunology, Section of Experimental Neurology, Department of Neurosciences, KU Leuven - University of Leuven, Leuven, Belgium.
Bruce Taylor23 Menzies Research Institute, University of Tasmania, Hobart, Australia.
Allan G Kermode24 Institute of Immunology and Infectious Diseases, Murdoch University, Australia 25 Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australia.
Pierre-Antoine Gourraud2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway.
International Multiple Sclerosis Genetics Consortium
Stephen J Sawcer27 Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Bettina Kullle Andreassen28 Department of Molecular Biology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Bénédicte Dubois1 Laboratory for Neuroimmunology, Section of Experimental Neurology, Department of Neurosciences, KU Leuven - University of Leuven, Leuven, Belgium 4 Department of Neurology, University Hospitals Leuven, KU Leuven - University of Leuven, Leuven, Belgium.
Hanne F Harbo2 Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway 3 Institute of Clinical Medicine, University of Oslo, Norway.
KU Leuven · BEKarolinska Institutet · SEOslo University Hospital · NOTechnical University of Munich · DEUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITVall d'Hebron Institut de Recerca · ESRigshospitalet · DKUCLouvain · BEUniversity of Oslo · NODanish Multiple Sclerosis Center · DKGriffith University · AUHaukeland University Hospital · NOHunter Medical Research Institute · AUMunich Cluster for Systems Neurology · DEMurdoch University · AUUniversitat Autònoma de Barcelona · ESUniversity of Bergen · NOUniversity of Cambridge · GBUniversity of Copenhagen · DKUniversity of Tasmania · AU

Funding

A Haplotype Map for Multiple SclerosisR01NS049477 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L · 2005 to 2014
$15.3M
NINDS NIH HHS R01 NS049477Wellcome Trust
6 · The paper itself

Abstract

Immunological hallmarks of multiple sclerosis include the production of antibodies in the central nervous system, expressed as presence of oligoclonal bands and/or an increased immunoglobulin G index-the level of immunoglobulin G in the cerebrospinal fluid compared to serum. However, the underlying differences between oligoclonal band-positive and -negative patients with multiple sclerosis and reasons for variability in immunoglobulin G index are not known. To identify genetic factors influencing the variation in the antibody levels in the cerebrospinal fluid in multiple sclerosis, we have performed a genome-wide association screen in patients collected from nine countries for two traits, presence or absence of oligoclonal bands (n = 3026) and immunoglobulin G index levels (n = 938), followed by a replication in 3891 additional patients. We replicate previously suggested association signals for oligoclonal band status in the major histocompatibility complex region for the rs9271640*A-rs6457617*G haplotype, correlated with HLA-DRB1*1501, and rs34083746*G, correlated with HLA-DQA1*0301 (P comparing two haplotypes = 8.88 × 10(-16)). Furthermore, we identify a novel association signal of rs9807334, near the ELAC1/SMAD4 genes, for oligoclonal band status (P = 8.45 × 10(-7)). The previously reported association of the immunoglobulin heavy chain locus with immunoglobulin G index reaches strong evidence for association in this data set (P = 3.79 × 10(-37)). We identify two novel associations in the major histocompatibility complex region with immunoglobulin G index: the rs9271640*A-rs6457617*G haplotype (P = 1.59 × 10(-22)), shared with oligoclonal band status, and an additional independent effect of rs6457617*G (P = 3.68 × 10(-6)). Variants identified in this study account for up to 2-fold differences in the odds of being oligoclonal band positive and 7.75% of the variation in immunoglobulin G index. Both traits are associated with clinical features of disease such as female gender, age at onset and severity. This is the largest study population so far investigated for the genetic influence on antibody levels in the cerebrospinal fluid in multiple sclerosis, including 6950 patients. We confirm that genetic factors underlie these antibody levels and identify both the major histocompatibility complex and immunoglobulin heavy chain region as major determinants.

Indexed as

Genetic VariationAdolescentAdultAgedChildChild, PreschoolEuropeFemaleGenetic Association StudiesHumansImmunoglobulin GMajor Histocompatibility ComplexMaleMiddle AgedMultiple SclerosisOligoclonal BandsELAC1 protein, humanImmunoglobulin GOligoclonal BandsSmad4 ProteinSMAD4 protein, humanTumor Suppressor ProteinsCSFgeneticsimmunoglobulinmultiple sclerosisoligoclonal bands

Identifiers

PMID25616667
PMCPMC4408440
OpenAlexW2166761601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.